Arbutus Biopharma Corporation (LON:0SGC)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 682.87M +40.9% |
| Revenue (ttm) | 144.98M +2,889.9% |
| Net Income | 121.71M |
| EPS | 0.63 |
| Shares Out | n/a |
| PE Ratio | 5.61 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 756 |
| Open | 3.280 |
| Previous Close | 3.309 |
| Day's Range | 3.280 - 3.319 |
| 52-Week Range | 2.365 - 4.675 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 19, 2026 |
About Arbutus Biopharma
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inh... [Read more]
Financial Performance
In 2025, Arbutus Biopharma's revenue was $14.08 million, an increase of 128.21% compared to the previous year's $6.17 million. Losses were -$33.50 million, -52.09% less than in 2024.
Financial numbers in USD Financial StatementsNews
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026
Arbutus Biopharma Quarterly report: Q2 2026
Arbutus Biopharma has published its Q2 2026 quarterly earnings report on August 12, 2026.
Arbutus Biopharma Earnings release: Q2 2026
Arbutus Biopharma released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Arbutus Biopharma expects to return $230M in capital to shareholders
Arbutus is also announcing that it expects to return capital to shareholders commencing in Q3 through repurchases of up to approximately $230M of the company’s common shares, which repurchases may…
Arbutus initiates patent infringement actions against Pfizer, BioNTech
Arbutus Biopharma (ABUS) and its exclusive licensee, Genevant Sciences, a subsidiary of Roivant (ROIV), announced the filing of three international lawsuits seeking to enforce patents protecting their...
Arbutus Biopharma receives $178M settlement agreement from Moderna
Arbutus (ABUS) also announced the receipt of approximately $178M from Moderna (MRNA), representing the company’s share of the noncontingent payment under the settlement agreement entered into with Mod...
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTec...
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna
Arbutus Biopharma Quarterly report: Q1 2026
Arbutus Biopharma has published its Q1 2026 quarterly earnings report on May 13, 2026.
Arbutus Biopharma Earnings release: Q1 2026
Arbutus Biopharma released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Arbutus Biopharma granted Fast Track designation for imdusiran
Arbutus Biopharma (ABUS) announced that the FDA has granted Fast Track designation for imdusiran for the treatment of chronic hepatitis B.
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdusiran WARMINSTER, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABU...
Arbutus Biopharma Proxy statement: Proxy filing
Arbutus Biopharma filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Arbutus Biopharma Proxy statement: Proxy filing
Arbutus Biopharma filed a proxy statement on April 14, 2026, providing details for shareholder voting and corporate governance matters.
Arbutus Biopharma price target lowered to $5.50 from $7 at Jefferies
Jefferies lowered the firm’s price target on Arbutus Biopharma (ABUS) to $5.50 from $7 and keeps a Buy rating on the shares. The key question post the Moderna (MRNA) settlement…
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025
Arbutus Biopharma Earnings release: Q4 2025
Arbutus Biopharma released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.
Arbutus Biopharma Annual report: Q4 2025
Arbutus Biopharma has published its Q4 2025 annual report on March 23, 2026.
Why Is Moderna (MRNA) Stock Surging Today, 3/4/26?
Moderna ($MRNA) stock is up by almost 9% in early trading on Wednesday after the vaccine maker announced it had settled patent litigation with Arbutus Biopharma ($ABUS) and Genevant Sciences.
Moderna resolves litigation with Arbutus, to pay up to $2.25B in settlement
As previously reported, Moderna (MRNA) announced that it has entered into a settlement agreement with Arbutus Biopharma (ABUS) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), resolving...
Moderna to Pay $950 Million to Settle Patent Cases From Arbutus, Genevant
The company will appeal to a federal circuit court to argue that it has limited liability due to its status as a government contractor.
Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute
Moderna has agreed to pay Genevant Sciences, a subsidiary of Roivant Sciences , and Arbutus Biopharma up to $2.25 billion to settle a long-running legal fight over the technology that made its ...
Genevant, Arbutus announce $2.25B global settlement with Moderna
Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), and Arbutus Biopharma Corporation (ABUS), announced that they have entered into a $2.25 billion global settlement with Moderna (MRNA) to res...
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna's Section 1498 appeal If the $1.3 billion payment is realized,...